B cells rapidly target antigen and surface-derived MHCII into peripheral degradative compartments.


Journal

Journal of cell science
ISSN: 1477-9137
Titre abrégé: J Cell Sci
Pays: England
ID NLM: 0052457

Informations de publication

Date de publication:
20 12 2019
Historique:
received: 30 06 2019
accepted: 20 11 2019
pubmed: 30 11 2019
medline: 22 9 2020
entrez: 30 11 2019
Statut: epublish

Résumé

In order to mount high-affinity antibody responses, B cells internalise specific antigens and process them into peptides loaded onto MHCII for presentation to T helper cells (T

Identifiants

pubmed: 31780582
pii: jcs.235192
doi: 10.1242/jcs.235192
pii:
doi:

Substances chimiques

Histocompatibility Antigens Class II 0
Receptors, Antigen, B-Cell 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2019. Published by The Company of Biologists Ltd.

Déclaration de conflit d'intérêts

Competing interestsThe authors declare no competing or financial interests.

Auteurs

Sara Hernández-Pérez (S)

Institute of Biomedicine, and MediCity Research Laboratories, University of Turku, 20014 Turku, Finland.
Turku Bioscience, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Marika Vainio (M)

Institute of Biomedicine, and MediCity Research Laboratories, University of Turku, 20014 Turku, Finland.
Turku Bioscience, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Elina Kuokkanen (E)

Institute of Biomedicine, and MediCity Research Laboratories, University of Turku, 20014 Turku, Finland.

Vid Šuštar (V)

Institute of Biomedicine, and MediCity Research Laboratories, University of Turku, 20014 Turku, Finland.

Petar Petrov (P)

Institute of Biomedicine, and MediCity Research Laboratories, University of Turku, 20014 Turku, Finland.
Turku Bioscience, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Sofia Forstén (S)

Institute of Biomedicine, and MediCity Research Laboratories, University of Turku, 20014 Turku, Finland.
Turku Bioscience, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Vilma Paavola (V)

Institute of Biomedicine, and MediCity Research Laboratories, University of Turku, 20014 Turku, Finland.

Johanna Rajala (J)

Institute of Biomedicine, and MediCity Research Laboratories, University of Turku, 20014 Turku, Finland.

Luqman O Awoniyi (LO)

Institute of Biomedicine, and MediCity Research Laboratories, University of Turku, 20014 Turku, Finland.
Turku Bioscience, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Alexey V Sarapulov (AV)

Institute of Biomedicine, and MediCity Research Laboratories, University of Turku, 20014 Turku, Finland.
Turku Bioscience, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Helena Vihinen (H)

Institute of Biotechnology, Electron Microscopy Unit, 00014 University of Helsinki, Finland.

Eija Jokitalo (E)

Institute of Biotechnology, Electron Microscopy Unit, 00014 University of Helsinki, Finland.

Andreas Bruckbauer (A)

Facility for Imaging by Light Microscopy (FILM), National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.

Pieta K Mattila (PK)

Institute of Biomedicine, and MediCity Research Laboratories, University of Turku, 20014 Turku, Finland pieta.mattila@utu.fi.
Turku Bioscience, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH